MDACC Study No:2012-1097 ( NCT No: NCT01838395)
Title:A Phase IIa Multicenter, Open-label Study Designed to Evaluate Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Principal Investigator:Gautam Borthakur
Treatment Agent:BL-8040; Cytarabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if BL-8040 in combination
with cytarabine can help to control relapsed or refractory AML. The safety of
the study drug combination will also be studied.

BL-8040 is designed to help cancer cells move from the bone marrow into the
bloodstream, where they are exposed to chemotherapy (in this case, cytarabine).

Cytarabine is designed to insert itself into the DNA (genetic material) of
cancer cells and stop the DNA from repairing itself. This may cause the cancer
cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:BL-8040
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:BioLineRX, Ltd.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults